In the first quarter of the fiscal year ending December 2026, sales reached \u00a513,197 million (up 10.6% YoY), operating profit was \u00a5837 million (up 35.4%), and net loss improved to \u00a532 million. The healthcare segment performed steadily, and the consolidated subsidiaries of Q’sai Group and Satis Pharmaceutical Group contributed to the growth of adjusted EBITDA, which expanded to \u00a51,821 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2931","jir_company_name":"Euglena Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/2931-20260514-01.pdf","jir_short_summary":"In the first quarter of the fiscal year ending December 2026, sales reached \u00a513,197 million (up 10.6% YoY), operating profit was \u00a5837 million (up 35.4%), and net loss improved to \u00a532 million. The healthcare segment performed steadily, and the consolidated subsidiaries of Q'sai Group and Satis Pharmaceutical Group contributed to the growth of adjusted EBITDA, which expanded to \u00a51,821 million.","jir_summary":"### Performance Overview\nEuglena Co., Ltd. achieved sales of \u00a513,197 million (up 10.6% YoY) in the first quarter of FY2026, with adjusted EBITDA expanding to \u00a51,821 million (up 17.8%). Operating profit increased significantly to \u00a5837 million (up 35.4%), and ordinary income rose sharply to \u00a5782 million (up 79.3%), maintaining profitability. The healthcare segment performed steadily, reflecting the effects of the consolidation of Q'sai Group and Satis Pharmaceutical Group subsidiaries. Net loss slightly narrowed, and the financial position remains solid.\n\n### Outlook and Impact on Shareholders\nLooking ahead, the company plans to expand advertising investments and explore new markets, while advancing the commercialization of its biofuel business through the construction of a commercial plant in Malaysia. Capital policy will include share buybacks and adjustments to capital reserves to balance shareholder returns and business growth. The company aims for sustained growth and continued profitability, evolving into an attractive enterprise for investors.","jir_financial_highlights":"Sales Revenue: \u00a513,197 million (Up 10.6% YoY)\nOperating Profit: \u00a5837 million (Up 35.4% YoY)\nNet Income attributable to Parent Company shareholders: \u25b3\u00a532 million (Compared to \u00a5\u25b3507 million in the same period last year)","jir_category":"","jir_hashtags":"#Euglena, #IRResults, #JapaneseStocks","jir_key_figures":"Sales Revenue: \u00a513,197 million (up 10.6% YoY)\nAdjusted EBITDA: \u00a51,821 million (up 17.8% YoY)\nNet Income attributable to Parent Company shareholders: \u25b3\u00a532 million (Last year's same period: \u00a5\u25b3507 million)","jir_meta_title":"\u3010Euglena\u3011Q1 FY2026 Financial Results | Sales of \u00a51.32 billion (+10%)","jir_meta_description":"Euglena Co., Ltd. achieved sales of \u00a513,197 million (up 10.6% YoY) in the first quarter of FY2026, with operating profit expanding to \u00a5837 million. The company will continue to promote business expansion and shareholder returns.","jir_og_title":"\u3010Euglena\u3011Q1 FY2026 Financial Results | Sales of \u00a51.32 billion (+10%)","jir_og_description":"Euglena's Q1 FY2026 financial results show sales of \u00a51.32 billion and operating profit of \u00a5837 million. Expectations for future business expansion and shareholder returns are high.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Q1 FY2025\\\", \\\"Q1 FY2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Sales Revenue\\\", \\\"data\\\": [11935, 13197], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Q1 FY2025\\\", \\\"Q1 FY2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Profit\\\", \\\"data\\\": [618, 837], \\\"borderColor\\\": \\\"#4BC0C0\\\", \\\"fill\\\": false}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Healthcare\\\", \\\"Biofuel\\\", \\\"Others\\\"], \\\"datasets\\\": [{\\\"data\\\": [12189, 256, 756], \\\"backgroundColor\\\": [\\\"#FF6384\\\", \\\"#36A2EB\\\", \\\"#FFCE56\\\"]}]}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Sales Revenue\\\", \\\"Operating Profit\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"FY2026 Q1\\\", \\\"data\\\": [13.2, 6.3], \\\"backgroundColor\\\": [\\\"#FF6384\\\", \\\"#4BC0C0\\\"]}]}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"headers\\\": [\\\"Indicator\\\", \\\"FY2026 Q1 Actual\\\", \\\"FY2026 Full Year Forecast\\\"], \\\"data\\\": [[\\\"Sales Revenue\\\", \\\"13,197\\\", \\\"52,000\\\"], [\\\"Operating Profit\\\", \\\"837\\\", \\\"3,200\\\"], [\\\"Net Profit\\\", \\\"\u25b332\\\", \\\"Unpublished\\\"]]}\"}]","ir_related_company":17302,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50934","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n